Caas Capital Management LP Prelude Therapeutics Inc Transaction History

Caas Capital Management LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 17, 2021	SELL	$39.27 - $91.68 $1.96 Million - $4.58 Million	-50,000 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$26.2 - $30.13 $1.31 Million - $1.51 Million	50,000 New	50,000 $1.51 Million

35.9M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $40.4M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.